Warp,

Thanks. Essentially the same answer/non-answer giving during July's Twitter Call.

Would it make sense for AMBS hold on to either or both until ready for market, then sell it to AMBSDX or another suitor ?

Are they looking for other DX's to purchase in order to round out Parkinson's Blood based testing / Breast Cancer Testing in order to follow what they have done for LymPro Test® "We are coalescing the ENTIRE Alzheimer Blood Based Biomarker Space" - GC

We now have ICON to help..

Dec.12'

Quote:

---

In addition, Amarantus has retained the services of Dr. Essam Sheta, former CLIA Laboratory Director at Power3, to assist the Company in preparing the Phase 2 validation study required to gain Clinical Laboratory Improvement Amendments (CLIA) certification. Upon CLIA certification, the Company intends to begin the commercial sale of the NuroPro® Parkinson's Disease Blood Test.

---

http://ir.stockpr.com/amarantus/company-news/...l-products

http://content.stockpr.com/amarantus/media/86...fdc838.pdf
slide 6 - NuroPro® for Breast Cancer

BC-SeraPro
http://www.reuters.com/article/2008/01/08/idU...BW20080108

Just interesting....

Cheers